1 results match your criteria: "Department of Urology JA Toride Sogo Iryo Center Toride Japan.[Affiliation]"
Introduction: Pembrolizumab is the standard therapy for urothelial carcinoma treatment; however, adverse events have been noted. Here, we report a rare case of vision loss as an immune-related adverse event of pembrolizumab therapy in a patient with metastatic renal pelvic cancer.
Case Presentation: A 69-year-old man treated with pembrolizumab for lung and lymph node metastases of renal pelvic cancer experienced significant vision loss in both eyes after 11 treatment cycles.